<DOC>
	<DOCNO>NCT02921919</DOCNO>
	<brief_summary>This single-arm , open-label , extended treatment , safety study patient treat talazoparib qualify study .</brief_summary>
	<brief_title>Open-Label Extension Safety Study Talazoparib</brief_title>
	<detailed_description />
	<mesh_term>Talazoparib</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 . Female patient childbearing potential must negative pregnancy test first dose talazoparib must agree use highly effective birth control method time first dose talazoparib 45 day last dose . Male patient must use condom sex pregnant woman woman childbearing potential time first dose talazoparib 105 day last dose . Contraception consider nonpregnant female partner childbearing potential . Female patient may breastfeed first dose talazoparib must breastfeed study participation 45 day last dose talazoparib . Permanently discontinue Medivation sponsor study talazoparib alone combination another agent . Received antineoplastic therapy investigational agent treatment talazoparib originate protocol . Has clinically significant cardiovascular , dermatologic , endocrine , gastrointestinal , hematologic , infectious , metabolic , neurologic , psychologic , pulmonary disorder condition , include excessive alcohol drug abuse , secondary malignancy , may interfere study participation opinion investigator . Diagnosis myelodysplastic syndrome ( MDS ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>